Clinic
Ascension Seton
Ascension Seton was paid $3.00M by Medicaid between Nov 2020 and Nov 2024, across 45 billing codes. Its largest line is 99283, emergency room visit (moderate) — 47% of everything it billed.
33Billing provider infoASCENSION SETON
KYLE, TX 78640
KYLE, TX 78640
33aNPI1619115383assigned 02/03/2009
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$3.00M
24GClaims44,228
24DCodes billed45
24AFirst – last monthNov 2020 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#105 of 320
Median peer was paid$205K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 172 | $16K | |
| 2021 | 10,771 | $736K | |
| 2022 | 16,597 | $1.17M | |
| 2023 | 12,156 | $800K | |
| 2024incomplete | 4,532 | $273K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 47% | 10,850 | 10,612 | $1.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 42% | 4,598 | 4,371 | $1.25M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 1,052 | 969 | $120K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.8% | 3,322 | 3,243 | $54K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.8% | 4,819 | 2,336 | $53K |
| 80053 | Comprehensive metabolic panel | <1% | 3,599 | 3,197 | $22K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 140 | 138 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,038 | 4,254 | $16K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 94 | 92 | $13K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 866 | 843 | $7K |
| 81001 | <1% | 2,686 | 2,497 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 986 | 915 | $5K |
33 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,114 | $5K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 58 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 661 | $3K |
| 87807 | <1% | 258 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 108 | $2K |
| 87070 | <1% | 463 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 60 | $2K |
| 84484 | <1% | 808 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 582 | $746.64 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 76 | $652.53 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 60 | $435.07 |
| 81025 | <1% | 64 | $381.40 | |
| 83690 | <1% | 199 | $363.11 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 193 | $341.36 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14 | $310.59 |
| 82803 | <1% | 94 | $174.11 | |
| 85610 | <1% | 306 | $136.44 | |
| 86901 | <1% | 77 | $97.63 | |
| 83605 | <1% | 110 | $96.71 | |
| 86900 | <1% | 77 | $95.12 | |
| 86850 | <1% | 12 | $85.66 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 151 | $83.97 |
| 83735 | <1% | 80 | $78.26 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 313 | $37.29 |
| 83880 | <1% | 14 | $32.98 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 98 | $21.56 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $11.73 |
| 85730 | <1% | 20 | $5.05 | |
| 82330 | <1% | 17 | $1.53 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 18 | $0.00 |
| A9270 | Non-covered item or service | 0% | 32 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 16 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOLLY, JULIE (REG DIR NET REV & REIMB)
Parent organizationASCENSION SETON
| Provider | Location | Paid |
|---|---|---|
| Cedar Park Health System LLC | Cedar Park, TX | $771K |
| Ascension Seton | Austin, TX | $511K |
| Ascension Seton | Elgin, TX | $94K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.